title: What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.
abstract: OBJECTIVE
  We previously reported that the concept of "platinum sensitivity" could be applied to recurrent endometrial cancer. We conducted an ancillary analysis to determine an appropriate second-line regimen for patients who received a platinum agent as first-line chemotherapy.
  
  
  METHODS
  We extracted and reanalyzed data of patients treated with doxorubicin and cisplatin (AP), paclitaxel and carboplatin (TC), or docetaxel and carboplatin (DC) as first- and second-line chemotherapies from the SGSG012/GOTIC004/Intergroup study.
  
  
  RESULTS
  We identified 216 patients: 38 received AP as first-line chemotherapy, of which 36 received TC or DC (Tax-C) as second-line chemotherapy; and 178 received Tax-C as first-line chemotherapy, of which 51 received AP and 127 received Tax-C as second-line chemotherapy. Median progression-free survival (PFS) and overall survival (OS) after second-line chemotherapy decreased in the order of Tax-C followed by Tax-C (10 and 48 months, respectively), AP followed by Tax-C (9 and 23 months, respectively), and Tax-C followed by AP (3 and 12 months, respectively). Median PFS and OS after second-line chemotherapy for platinum-resistant patients receiving Tax-C as first-line chemotherapy were longer in Tax-C than in AP (7 and 23 vs. 3 and 10 months, respectively) as second-line chemotherapy [hazard ratio (HR) 3.255, 95 % confidence interval (CI) 1.908-5.555, p < 0.0001; HR 3.179, 95 % CI 1.835-5.507, p < 0.0001, respectively]. Median PFS and OS after second-line chemotherapy for platinum-sensitive patients receiving Tax-C as first-line chemotherapy were almost equivalent to those receiving Tax-C or AP as second-line chemotherapy.
  
  
  CONCLUSIONS
  For platinum-resistant recurrent endometrial cancer patients, Tax-C may be preferred over AP as second-line chemotherapy.
authors.affiliation: Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi City, Hyogo, 673-8558, Japan, nagao@hp.pref.hyogo.jp.
authors.forename: Shoji
authors.initials: S
authors.lastname: Nagao
authors.forename: Shin
authors.initials: S
authors.lastname: Nishio
authors.forename: Satoshi
authors.initials: S
authors.lastname: Okada
authors.forename: Takeo
authors.initials: T
authors.lastname: Otsuki
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Fujiwara
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tanabe
authors.forename: Masashi
authors.initials: M
authors.lastname: Takano
authors.forename: Yoko
authors.initials: Y
authors.lastname: Hasumi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Takei
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Hasegawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fujiwara
authors.forename: Munetaka
authors.initials: M
authors.lastname: Takekuma
authors.forename: Kazuto
authors.initials: K
authors.lastname: Nakamura
authors.forename: Muneaki
authors.initials: M
authors.lastname: Shimada
authors.forename: Mitsuaki
authors.initials: M
authors.lastname: Suzuki
authors.forename: Junzo
authors.initials: J
authors.lastname: Kigawa
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin